Neurological deterioration in a patient with HIV-associated cryptococcal meningitis initially improving on antifungal treatment : a case report of coincidental racemose neurocysticercosis
© 2021. The Author(s)..
BACKGROUND: Managing HIV-associated cryptococcal meningitis (CM) can become challenging in the presence of concurrent unusual central nervous system infections.
CASE PRESENTATION: A 58-year old HIV infected woman new ART starter, who was being treated effectively for cryptococcal meningitis, represented with worsening of neurological symptoms. Brain MRI revealed a multicystic lesion in the left temporal lobe. Anti-fungal treatment was escalated for a suspected cryptococcoma, but post-mortem CSF serological test confirmed racemose neurocysticercosis.
CONCLUSION: Patients with HIV-associated CM are highly immunocompromised and may have multiple pathologies simultaneously. In endemic countries, neurocysticercosis should be considered in the differential diagnosis where there is central nervous system deterioration despite effective therapy for CM.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:21 |
|---|---|
| Enthalten in: |
BMC infectious diseases - 21(2021), 1 vom: 31. Juli, Seite 724 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kalata, Newton [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antifungal Agents |
|---|
| Anmerkungen: |
Date Completed 24.09.2021 Date Revised 24.09.2021 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1186/s12879-021-06425-9 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM328771228 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM328771228 | ||
| 003 | DE-627 | ||
| 005 | 20231225203643.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s12879-021-06425-9 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1095.xml |
| 035 | |a (DE-627)NLM328771228 | ||
| 035 | |a (NLM)34332543 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kalata, Newton |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Neurological deterioration in a patient with HIV-associated cryptococcal meningitis initially improving on antifungal treatment |b a case report of coincidental racemose neurocysticercosis |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 24.09.2021 | ||
| 500 | |a Date Revised 24.09.2021 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2021. The Author(s). | ||
| 520 | |a BACKGROUND: Managing HIV-associated cryptococcal meningitis (CM) can become challenging in the presence of concurrent unusual central nervous system infections | ||
| 520 | |a CASE PRESENTATION: A 58-year old HIV infected woman new ART starter, who was being treated effectively for cryptococcal meningitis, represented with worsening of neurological symptoms. Brain MRI revealed a multicystic lesion in the left temporal lobe. Anti-fungal treatment was escalated for a suspected cryptococcoma, but post-mortem CSF serological test confirmed racemose neurocysticercosis | ||
| 520 | |a CONCLUSION: Patients with HIV-associated CM are highly immunocompromised and may have multiple pathologies simultaneously. In endemic countries, neurocysticercosis should be considered in the differential diagnosis where there is central nervous system deterioration despite effective therapy for CM | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Cryptococcal meningitis | |
| 650 | 4 | |a HIV | |
| 650 | 4 | |a Racemose neurocysticercosis | |
| 650 | 7 | |a Antifungal Agents |2 NLM | |
| 700 | 1 | |a Ellis, Jayne |e verfasserin |4 aut | |
| 700 | 1 | |a Benjamin, Laura |e verfasserin |4 aut | |
| 700 | 1 | |a Kampondeni, Samuel |e verfasserin |4 aut | |
| 700 | 1 | |a Chiodini, Peter |e verfasserin |4 aut | |
| 700 | 1 | |a Harrison, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Lalloo, David G |e verfasserin |4 aut | |
| 700 | 1 | |a Heyderman, Robert S |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t BMC infectious diseases |d 2001 |g 21(2021), 1 vom: 31. Juli, Seite 724 |w (DE-627)NLM11120089X |x 1471-2334 |7 nnns |
| 773 | 1 | 8 | |g volume:21 |g year:2021 |g number:1 |g day:31 |g month:07 |g pages:724 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1186/s12879-021-06425-9 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 21 |j 2021 |e 1 |b 31 |c 07 |h 724 | ||